Compare Cognizant Technology Solutions Corp (CTSH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Neurocrine Biosciences Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.82 (market cap $27.03B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Cognizant Technology Solutions Corp is the larger of the two by market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CTSH | NBIX | |
|---|---|---|
Market Cap | $27.03B | $14.36B |
Volume | 9,883,888 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $86.70 | $185.50 |
52-Week Low | $38.73 | $123.10 |
Typical Hold Time | 57 Days | 23 Days |
Enterprise Value | $28.08B | $14.37B |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% with bearish technical signals despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 12.25 and EV/EBITDA of 6.52, while maintaining solid profitability with 10.26% net margin. Recent news highlights the company's AI transformation initiatives and recognition as a top employer, though Q2 2026 earnings missed expectations.
CTSH presents a compelling value opportunity with strong fundamentals and analyst consensus target of $64.25 (12.6% upside). Risks include IT spending pressures from AI disruption and competitive threats. The upcoming Q3 2026 earnings report on October 29, 2026 will be critical for validating the company's growth trajectory amid industry headwinds.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
